BLASUBCUTANEOUSSOLUTION
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TOUJEO MAX SOLOSTAR (insulin glargine) by Sanofi. Approved for type 2 diabetes mellitus, type 1 diabetes mellitus, diabetes mellitus. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOUJEO MAX SOLOSTAR is a long-acting basal insulin analog (insulin glargine) administered via subcutaneous injection in a pre-filled pen delivery system. It is indicated for glycemic control in patients with diabetes mellitus who require insulin therapy. The product represents a higher-concentration formulation of insulin glargine designed to reduce injection volume while maintaining therapeutic efficacy. TOUJEO MAX SOLOSTAR occupies a premium position within the basal insulin class, competing against multiple insulin analogs and newer GLP-1 receptor agonists for diabetes management.
$0.5BPart D
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications (3)
Worked on TOUJEO MAX SOLOSTAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.